Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Early Phase 1
1(20.0%)
5Total
Phase 2(4)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06645821Early Phase 1Recruiting

Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%

Role: lead

NCT04906655Phase 2Completed

An Open Label Study for Palmar Hyperhydrosis

Role: collaborator

NCT00987545Phase 2Terminated

Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence

Role: collaborator

NCT00274352Phase 2Completed

A Study of Adalimumab to Treat Sarcoidosis of the Skin

Role: collaborator

NCT01041625Phase 2Unknown

Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus

Role: lead

All 5 trials loaded